Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of MAPK signal pathway inhibitor to preparation of drugs for treating cystic echinococcosis

A cystic hydatid disease and signal pathway technology, which is applied in the application field of preparing a drug for treating cystic hydatid disease

Active Publication Date: 2016-04-20
THE FIRST TEACHING HOSPITAL OF XINJIANG MEDICAL UNIVERCITY
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the MAPK signaling pathway inhibitors Sorafenib, U0126 and PD184352 with anti-tumor effects have not been reported, and they can be applied to the treatment of cystic echinococcosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of MAPK signal pathway inhibitor to preparation of drugs for treating cystic echinococcosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0013] Example 1: The application of the MAPK signaling pathway inhibitor as a drug for the preparation of cystic echinococcosis.

Embodiment 2

[0014] Example 2: As an optimization of the above examples, the MAPK signaling pathway inhibitor is Sorafenib tosylate tablets (Sorafenib) or U0126 or PD184352.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to View More

Abstract

The invention relates to the technical field of an MAPK signal pathway inhibitor, in particular to application of the MAPK signal pathway inhibitor to preparation of drugs for treating cystic echinococcosis. The invention discloses for the first time the application of the MAPK signal pathway inhibitor to preparation of drugs for treating cystic echinococcosis, and further discloses for the first time application of Sorafenib Tosylate Tablets, U0126 or PD184352 in the MAPK signal pathway inhibitor to preparation of drugs for treating cystic echinococcosis. Pharmacodynamic experimental data show that the treating effect of Sorafenib Tosylate Tablets, U0126 or PD184352 on cystic echinococcosis is superior or equivalent to that of clinically commonly used albendazole on cystic echinococcosis, that is, the MAPK signal pathway inhibitor can serve as a novel anti-echinococcosis drug for cystic echinococcosis, especially Sorafenib Tosylate Tablets, U0126 or PD184352, which can serve as a novel anti-echinococcosis drug, so that a novel approach is provided for cystic echinococcosis treatment.

Description

technical field [0001] The invention relates to the application technical field of MAPK signaling pathway inhibitors, and relates to the application of a MAPK signaling pathway inhibitor as a medicine for treating cystic echinococcosis. Background technique [0002] Echinococcosis, which is distributed worldwide, is also known as echinococcosis. Its larvae parasitize the human body and will cause serious zoonotic diseases. There are currently four recognized species, namely, E. granulosus (E.g), E. oligarthtus (E.o), E. multilocularis (E.m) and E. Echinococcus fowleri (E.vogeli, E.v), however, 95% of the cases are cystic echinococcosis (CystisEchinococccosis, CE) caused by Echinococcus granulosus (E.g) infection. Inner Mongolia, Sichuan, Gansu, Ningxia, Xinjiang, Qinghai and other seven provinces are high-incidence areas. The threatened population has reached 66 million, and the annual economic loss has exceeded 3 billion yuan. In 2006, China included it in the health plan...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K31/44A61K31/277A61K31/166A61P33/02
CPCA61K31/166A61K31/277A61K31/44A61K45/00
Inventor 温浩张传山林仁勇吕国栋赵军王建华李红林李亮毕晓娟
Owner THE FIRST TEACHING HOSPITAL OF XINJIANG MEDICAL UNIVERCITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com